



## 1.0 PURPOSE

The purpose of this document is to describe the process of determining the particle size distribution of mRNA encapsulated lipid nanoparticle (LNP), [REDACTED], and Drug Product (DP) using Dynamic Light Scattering (DLS).

This method incorporates the utilization of [REDACTED] filtration of the sample prior to DLS analysis, removing particles [REDACTED] from the solution, thereby providing a higher quality dataset corresponding to the submicron size range.

## 2.0 SCOPE

This method applies to cGMP release and stability particle size analysis of final mRNA LNP, [REDACTED], and DP samples.

## 3.0 REFERENCED DOCUMENTS

Document #	Title
SOP-0017	Maintaining a RNase Free Work Environment
SOP-0033	Out of Specification (OOS)
SOP-0081	Preparation of Solutions and Samples in the GMP-Quality Control Laboratory
SOP-0227	[REDACTED] Operation and Maintenance
SOP-0333	Operation and Maintenance of [REDACTED]
SOP-0403	QC [REDACTED] Operations Procedure
SOP-0409	Quality Control Invalid Assay Procedure
FRM-0120	General Quality Control Sample Submission Form
FRM-0180	Quality Control Solution Preparation Form
FRM-0728	SOP-0998 Assay Performance Worksheet
DPAD-FRM-0010	[REDACTED] Form

#### 4.0 RESPONSIBILITIES

Department/ Functional Area	Responsibility
Department Manager or Designee	<ul style="list-style-type: none"> <li>Ensuring that laboratory personnel are properly trained in this procedure.</li> <li>Ensuring that all procedures outlined in this document are followed when applicable.</li> <li>Ensuring that this procedure is revised as necessary.</li> </ul>
Laboratory Personnel	<ul style="list-style-type: none"> <li>Following procedures outlined in this document, when applicable.</li> <li>Recording assay performance using FRM-0728.</li> <li>Maintaining an RNase free work environment per SOP-0017.</li> <li>Preparing solutions and samples per SOP-0081.</li> <li>Following proper safety standards in the laboratory.</li> </ul>

#### 5.0 DEFINITIONS

Term	Definition
μL	Microliter
DP	Drug Product
L	Liter
LNP	Lipid Nanoparticle
mL	Milliliter
mRNA	Messenger Ribonucleic Acid
NaCl	Sodium Chloride
ng	Nanogram
PBS	Phosphate Buffered Saline
S	Seconds
WS	Working Solution

#### 6.0 EQUIPMENT AND MATERIALS

Equivalent equipment, consumables and materials can be used, unless otherwise indicated, and provided they match the reagent grade or specifications.

##### Equipment

Description	Supplier	Catalog Number

Description	Supplier	Catalog Number
Pipettes, capable of measuring [REDACTED]	[REDACTED]	[REDACTED]
Vortex	[REDACTED]	[REDACTED]

### Reagents

Use the reagents specified below or equivalent.

Description	Supplier	Catalog or Part Number
[REDACTED]		

### Materials

Description	Supplier	Catalog Number
[REDACTED]		

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Description	Supplier	Catalog Number
[REDACTED]		

## 7.0 SAFETY

- 7.1. Laboratory personnel must wear appropriate PPE when working in the QC Laboratory.
- 7.2. Removal of the [REDACTED] main covers by unauthorized personnel, even a supervisor, will invalidate the warranty of the instrument. Failure to follow these guidelines could result in exposure to hazardous voltages and laser radiation.

## 8.0 PROCEDURE

Reagent and sample preparations may be scaled accordingly, such that the predetermined concentrations are maintained. Prepare and label all solutions per SOP-0081.

### 8.1. Sample and Standard Preparation

#### 8.1.1. [REDACTED]


##### 8.1.1.1. [REDACTED]

SOP-0403.

##### 8.1.1.2. [REDACTED]


SOP-0403.

8.1.1.3.




SOP-0403.

8.1.2.



8.1.2.1.



8.1.2.2.

8.1.2.3.


8.1.2.4.

8.1.3.



8.1.3.1.

8.1.3.2.



8.1.3.3.

8.1.3.4.

$$\text{Amount of sample } (\mu\text{L}) = \frac{\text{final sample concentration } (\mu\text{g/mL})}{\text{Initial sample concentration } (\frac{\text{mg}}{\text{mL}})} * \mu\text{L}$$

$$\text{Amount of } (\mu\text{L}) = \mu\text{L} - \text{Sample } (\mu\text{L})$$

8.1.3.5.

8.1.3.6.

8.1.3.7.

8.1.3.8.

8.1.4.

8.1.4.1.

8.1.4.2.

8.1.4.3.

8.1.4.4.

$$\text{Amount of sample } (\mu\text{L}) = \frac{\text{final sample concentration } (\text{mg/mL})}{\text{Initial sample concentration } (\frac{\text{mg}}{\text{mL}})} * \text{ } \mu\text{L}$$

$$\text{Amount of } (\mu\text{L}) = \text{ } \mu\text{L} - \text{Amount of Sample } (\mu\text{L})$$

8.1.4.5.

8.1.4.6.

8.1.4.7.

8.1.4.8.

## 8.2. Instrument Setup

8.2.1. SOP-0333

8.2.2.

8.2.3.

SOP-0333.

8.2.3.1.

8.2.3.2.

SOP-0998

8.2.4.

8.2.5.

[REDACTED]

8.2.6.

[REDACTED] SOP-0333.

Table 1: [REDACTED] SOP-0998 [REDACTED]


		Parameters	
Measurement type:			
Parameter	Property	Specification	Comment
Sample	[REDACTED]	[REDACTED]	[REDACTED]
			[REDACTED]
			[REDACTED]
			[REDACTED]
Measurement	Measurement angle	[REDACTED]	[REDACTED]
	Measurement duration		[REDACTED]
	Advanced		[REDACTED]
Data Processing	Analysis model:	[REDACTED]	[REDACTED]



**Table 2: Instrument Method for SOP-0998**

Parameters			
Measurement type			
Parameter	Property	Specification	Comment
Sample			
Measurement	Measurement angle		
	Measurement duration		
	Advanced		
Data Processing	Analysis model:		

### 8.3. System Suitability Verification Using Standards



8.3.1.

8.3.2.

8.3.3.

8.3.4.

8.3.5.

8.3.5.1.

8.3.6.

**Table 3: Standard Dispersant Parameters**

Solvent	Temperature (°C)	RI	Viscosity (cP)	Dielectric Constant

8.3.7.

8.3.8.

#### 8.4. Testing

8.4.1.

8.4.2.

8.4.3.

8.4.3.1.

8.4.3.2.

8.4.4.

8.4.5.

8.4.5.1.

8.4.5.2.

8.4.6.

8.4.7.

8.4.8.

8.4.8.1.

8.4.8.2.

8.4.9.

8.4.10.

8.4.11.

8.4.12.

**Table 4: Sample Sequence Example**

Line #	Sample
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	

## 8.5. Acceptance Criteria

### 8.5.1. System Suitability Criteria

8.5.1.1. Refer to Table 5 for the System Suitability Criteria.

**Table 5: System Suitability Acceptance Criteria**

Size Standard	Particle Size Z-Average (diameter, nm) Acceptable Range	Polydispersity Index (Pdl)

## 8.5.2. Sample Acceptance Criteria

8.5.2.1.

8.5.2.2.

8.5.2.3.

## 8.6. Reporting Results

8.6.1. Follow **SOP-0082** for QC data reporting.

8.6.2.

8.6.3.

8.6.3.1.

8.6.3.2.

8.6.3.3.

8.6.3.4.

8.6.4.

8.6.4.1.

8.6.4.2.

8.6.4.3.

8.6.4.4.

8.6.5.

SOP-0227.

8.6.5.1.

8.6.5.2.

8.6.6.

SOP-0033

8.6.7.

SOP-0409


## 9.0 ATTACHMENTS

- 9.1. Attachment 1: Example of a [REDACTED] with Result Quality Acceptable.
- 9.2. Attachment 2: Example of a [REDACTED] with Result Quality Unacceptable
- 9.3. Attachment 3: Example of a [REDACTED] with Multimodal Result
- 9.4. Attachment 4: New SOP Creation with Dispersant Selection

## 10.0 REVISION HISTORY


Revision #	Effective Date	Change Details	Author
1.0	Refer to Veeva Header for Effective Date	New Document	[REDACTED]

**ATTACHMENT 1 - Example of a [REDACTED] with Result Quality Acceptable**  
(Page 1 of 2)







**ATTACHMENT 1 - Example of a [REDACTED] with Result Quality Acceptable**  
(Page 2 of 2)




**ATTACHMENT 2 - Example of a [REDACTED] with Result Quality Unacceptable**  
(Page 1 of 2)




**ATTACHMENT 2 - Example of a [REDACTED] with Result Quality Unacceptable**  
(Page 2 of 2)



**ATTACHMENT 3 - Example of a [REDACTED] with Multimodal Results**  
(Page 1 of 1)




**ATTACHMENT 4 - New SOP Creation with Dispersant Selection**  
(Page 1 of 2)



CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

**ATTACHMENT 4 - New SOP Creation with Dispersant Selection**  
(Page 2 of 2)



CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Document Approvals  
Approved Date: 05 Oct 2020

Approval Verdict: Approved	<div></div> Quality Control Approval 01-Oct-2020 02:47:11 GMT+0000
QA Approval Verdict: Approved	<div></div> Quality Assurance Approval 01-Oct-2020 16:24:48 GMT+0000

This document cannot be used to support any marketing authorisation application and any extensions or variations thereof  
ema.europa.eu  
Released under Regulation (EC) No 1049/2001 on 24 February 2022